Vasopressin receptor antagonists: Pharmacological tools and potential therapeutic agents

Autonomic and Autacoid Pharmacology

Volumn 26, Issue 2, 2006, Pages 141-148

  Streefkerk, J O ^a   Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Congestive heart failure; Hypertension; Presynaptic V1 receptors; Sympathetic neurones; Syndrome of inappropriate antidiuretic hormone; Vasopressin receptor antagonists; Vasopressin receptors

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 1 [5 CHLORO 3 (2 CHLOROPHENYL) 1 (3,4 DIMETHOXYBENZENESULFONYL) 2,3 DIHYDRO 3 HYDROXY 1H INDOLE 2 CARBONYL] 2 PYRROLIDINECARBOXAMIDE; CONIVAPTAN; FR 161282; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; RELCOVAPTAN; SR 12143B; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR; VP 339; VP 343; WAY 140288;

BINDING AFFINITY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; NONHUMAN; PRESYNAPTIC NERVE; REVIEW; SYMPATHETIC NERVE CELL;

ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; DRUG DESIGN; HEART FAILURE, CONGESTIVE; HORMONE ANTAGONISTS; HUMANS; HYPERTENSION; INAPPROPRIATE ADH SYNDROME; INDOLES; PRESYNAPTIC TERMINALS; PYRROLIDINES; RECEPTORS, VASOPRESSIN; RENAL ARTERY; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 33645294919     PISSN: 14748665     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1474-8673.2006.00361.x     Document Type: Review

References (33)

1. AKI Y. TAMAKI T. KIYOMOTO H. HE H. YOSHIDA H. IWAO H. ABE Y. 1994 Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. J. Cardiovasc. Pharmacol. 23 331 336.
2. BAKRIS G. BURSZTYN M. GAVRAS I. BRESNAHAN M. GAVRAS H. 1997 Role of vasopressin in essential hypertension: racial differences. J. Hypertens. 15 545 550.
3. BURRELL L.M. PHILLIPS P.A. STEPHENSON J.M. RISVANIS J. ROLLS K.A. JOHNSTON C.I. 1994 Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 23 737 743.
4. BURSZTYN M. BRESNAHAN M. GAVRAS I. GAVRAS H. 1990 Pressor hormones in elderly hypertensive persons. Racial Differ. Hypertens. 15 I88 I92.
5. COWLEY A.W. Jr. MERRILL D. OSBORN J. BARBER B.J. 1984 Influence of vasopressin and angiotensin on baroreflexes in the dog. Circ. Res. 54 163 172.
6. DECAUX G. 2001 Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am. J. Med. 110 582 584.
7. DEN OUDEN D.T. MEINDERS A.E. 2005 Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Neth. J. Med. 63 4 13.
8. GARCIA-VILLALON A.L. MONGE L. FERNANDEZ N. SANCHEZ M.A. MARTINEZ M.A. GOMEZ B. DIEGUEZ G. 2000 Impaired potentiation by endothelin-1 and vasopressin of sympathetic contraction in tail artery from hypertensive rats. Cardiovasc. Res. 45 463 469.
9. GAVRAS H. 1991 Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin. Chem. 37 1828 1830.
10. GERBES A.L. GULBERG V. GINES P. DECAUX G. GROSS P. GANDJINI H. DJIAN J. 2003 Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124 933 939.
11. GHEORGHIADE M. GATTIS W.A. O'CONNOR C.M. et al. 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 1963 1971.
12. GHEORGHIADE M. ORLANDI C. BURNETT J.C. et al. 2005 Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. 11 260 269.
13. LOLAIT S.J. O'CARROLL A.M. MAHAN L.C. FELDER C.C. BUTTON D.C. YOUNG W.S. III. MEZEY E. BROWNSTEIN M.J. 1995 Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl Acad. Sci. USA 92 6783 6787.
14. MATURI M.F. MARTIN S.E. MARKLE D. MAXWELL M. BURRUSS C.R. SPEIR E. GREENE R. RO Y.M. VITALE D. GREEN M.V. 1991 Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation 83 2111 2121.
15. MEDINA P. ACUNA A. MARTINEZ-LEON J.B. OTERO E. VILA J.M. ALDASORO M. LLUCH S. 1998 Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein. Circulation 97 865 870.
16. OS I. KJELDSEN S.E. SKJOTO J. WESTHEIM A. LANDE K. AAKESSON I. FREDERICHSEN P. LEREN P. HJERMANN I. EIDE I.K. 1986 Increased plasma vasopressin in low renin essential hypertension. Hypertension 8 506 513.
17. ROBERTSON G.L. 2001 Antidiuretic hormone. Normal and disordered function. Endocrinol. Metab. Clin. North Am. 30 671 694 vii.
18. RUSSELL S.D. SELARU P. PYNE D.A. GHAZZI M.M. MASSEY K.D. PRESSLER M. SERIKOFF A. COATS A.J. 2003 Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 145 179 186.
19. SEGARRA G. MEDINA P. VILA J.M. CHUAN P. DOMENECH C. LLUCH S. 2002 Increased contraction to noradrenaline by vasopressin in human renal arteries. J. Hypertens. 20 1373 1379.
20. SERRADEIL-LE GAL C. WAGNON J. VALETTE G. GARCIA G. PASCAL M. MAFFRAND J.P. LE FUR G. 2002 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res. 139 197 210.
21. SKJOTO J. AAKESSON I. OS I. KJELDSEN S.E. EIDE I. LEREN P. 1984 Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension. Acta Med. Scand. 215 165 172.
22. SONNENBURG W.K. SMITH W.L. 1988 Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J. Biol. Chem. 263 6155 6160.
23. STREEFKERK J.O. MATHY M.J. PFAFFENDORF M. VAN ZWIETEN P.A. 2002 Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat. J. Hypertens. 20 1175 1180.
24. STREEFKERK J.O. PFAFFENDORF M. VAN ZWIETEN P.A. 2003a Endothelium-dependent, vasopressin-induced contractions in rabbit renal arteries. J. Cardiovasc. Pharmacol. 42 703 709.
25. STREEFKERK J.O. PFAFFENDORF M. VAN ZWIETEN P.A. 2003b Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent. Auton. Autacoid. Pharmacol. 23 35 41.
26. STREEFKERK J.O. BALT J.C. VAN MONTFRANS G.A. VAN LIESHOUT J.J. PFAFFENDORF M. VAN ZWIETEN P.A. 2004 Vasopressin facilitates presynaptic sympathetic nerve activity in humans. J. Hypertens. 22 551 555.
27. THIBONNIER M. KILANI A. RAHMAN M. DIBLASI T.P. WARNER K. SMITH M.C. LEENHARDT A.F. BROUARD R. 1999 Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 34 1293 1300.
28. UDELSON J.E. SMITH W.B. HENDRIX G.H. et al. 2001 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 2417 2423.
29. VAN LIEBURG A.F. KNOERS N.V. MONNENS L.A. SMITS P. 1995 Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect. J. Hypertens. 13 1695 1700.
30. WENZEL V. KRISMER A.C. ARNTZ H.R. SITTER H. STADLBAUER K.H. LINDNER K.H. 2004 A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N. Engl. J. Med. 350 105 113.
31. WONG L.L. VERBALIS J.G. 2001 Vasopressin V2 receptor antagonists. Cardiovasc. Res. 51 391 402.
32. WONG F. BLEI A.T. BLENDIS L.M. THULUVATH P.J. 2003 A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37 182 191.
33. XU Y.J. GOPALAKRISHNAN V. 1991 Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. 69 239 245.